Anika Therapeutics Reports Q3 2026 Revenue Growth and Improved Profitability
Anika Therapeutics (ANIK) reported third-quarter 2026 revenue of $30.6 million, a 10% increase driven by record performance in its commercial channel ($14.0 million) and steady growth in the OEM channel ($16.6 million). The company demonstrated significant margin expansion, with gross margins rising to 62% from 56% in the prior-year period due to manufacturing productivity gains. Adjusted EBITDA saw a substantial increase to $5.1 million compared to $900,000 in the previous year. Strategic developments include a new 10-year distribution agreement for Hyvisc with Boehringer Ingelheim and progress on the Cingal NDA timeline, which is expected by late 2027. While management raised full-year 2026 revenue and EBITDA margin guidance, they cautioned that elective surgical procedures in the U.S. were slower than usual this quarter and warned of potential pricing declines in the U.S. OA pain market heading into 2027.
Topics: adjusted EBITDA commercial channel performance gross margin expansion revenue growth